Vertex Pharmaceuticals price target raised to $476 from $473 at Morgan Stanley
The Fly

Vertex Pharmaceuticals price target raised to $476 from $473 at Morgan Stanley

Morgan Stanley analyst Terence Flynn raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $476 from $473 and keeps an Equal Weight rating on the shares after Q3 results came in ahead of consensus and the company raised 2024 revenue guidance by about 1% at the midpoint. The next catalyst for the stock will be the suzetrigine Phase 2 lumbosacral radiculopathy, or LSR data, that are still expected by year-end, the analyst tells investors.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App